Agilent Technologies expanded FDA approval for its Keytruda companion diagnostic, enabling its PD-L1 IHC 22C3 pharmDx Code GE006 assay to be used across additional cancers on the automated Dako Omnis platform. The update broadens the menu of malignancies that can be stratified using the same standardized workflow, strengthening the path for scaled adoption in routine pathology settings. The approval centers on automating the testing process on Dako Omnis, a key differentiator for high-throughput labs managing payer and guideline-driven demand for biomarker testing. For clinicians, it supports consistent PD-L1 assessment tied to pembrolizumab treatment decisions. From an industry perspective, the move also underlines the continued regulatory momentum around IHC-based CDx products as oncology programs expand. As PD-(L)1 testing becomes further embedded in clinical pathways, platform-enabled automation is increasingly positioned as a compliance and throughput advantage. Overall, Agilent’s expanded clearance is an operational update with downstream implications for diagnostic availability and turnaround times across accredited testing sites.